Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POETYK PsA-2
2020-005099-36Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deucravacitinib in psoriatic arthritis (PsA) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of participants meeting American College of Rheumatology improvement of 20% (ACR20). Started Jun 2021; status: active.
02
Drugs
deucravacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2020-005099-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005099-36.